PathMaker Neurosystems

Executive Summary

PathMaker Neurosystems is a clinical-stage neuromodulation company based in Boston, developing non-invasive devices to treat amyotrophic lateral sclerosis (ALS) and other serious neurological disorders. The company's platform targets neuronal hyperexcitability and activates protein degradation pathways, building on extensive preclinical work. PathMaker aims to offer a transformative, non-invasive alternative for ALS patients, where current treatments remain limited. With a strong scientific foundation and a clear focus on a high-need indication, the company is positioned to address significant unmet medical needs in neurology.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 clinical trial for non-invasive ALS treatment40% success
• Q2 2026Series A financing round to support clinical development60% success
• Q1 2026Publication of preclinical data in peer-reviewed journal80% success